PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a systematic review and meta-analysisFrancesco Schettini, Tomas Pascual, Benedetta Conte, Nuria Chic, Fara Brasò-Maristany, Patricia Galvàn, Olga Martìnez, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Aranzazu Fernandez-Martinez, Carla Rognoni, Gaia Griguolo, Valentina Guarneri, Pierfranco Conte, Mariavittoria Loccia, Jan Brase, Blanca Gonzalez-Farre, Patricia Villagrasa, Sabino De Placido, Rachel Schiff, Mothaffar Rimawi, C Osborne, Sonia Pernas, Charles Perou … & Aleix Prat
HER2-positive (HER2+) breast cancer (BC) comprises all the PAM50 intrinsic molecular subtypes (Luminal A, Luminal B, HER2-E and Basal-like). Among them, the HER2-E is associated with higher pathological complete response (pCR) rates compared to non-HER2-E disease following anti-HER2-based regimens, with or without chemotherapy (CT). Here, we present a trial-level metanalysis to validate the association of the HER2-E subtype with pCR.
This data center is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.
We found no citations for this text. For information on how to provide citation information, please see our documentation.